304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2023-11-28

Henlius Xuhui Facility Passes Colombian GMP Inspection for HANLIKANG
2023-11-27

Henlius Receives the FDA IND Approval for Its PD-L1-Targeting ADC Candidate HLX43
2023-11-24

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX43
2023-11-23

Henlius Receives the FDA IND Approval for Its EGFR-Targeting ADC Candidate HLX42
2023-11-22

Henlius Announces Upcoming Mini Oral Presentation and Five Posters at the ESMO Asia 2023
2023-11-20

Henlius’ Second U.S. Clinical Investigators Meeting: In-Depth Exploration of Small Cell Lung Cancer Treatment Innovations
2023-11-15

Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 Billion, Profitability Further Improved
2023-10-31

Phase 3 Clinical Study of HANSIZHUANG in Combination with Chemotherapy for Treatment on Patients with non-squamous NSCLC Met Primary Endpoint
2023-10-30

Henlius Showcases Innovations and Strengthens International Collaboration at CPHI Worldwide 2023